About: Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis
Creator	Slavin, Monica Teh, Benjamin Thursky, Karin Worth, Leon Haeusler, Gabrielle Lingaratnam, Senthil Seymour, John Tam, Constantine Correspondence, Gabrielle Haeusler,
Source	PMC
abstract	OBJECTIVE: Fludarabine, cyclophosphamide and rituximab (FCR) therapy for lymphoid malignancies has historically been associated with a low reported incidence of Pneumocystis jirovecii pneumonia (PJP). However, prophylaxis was routinely used in early studies, and molecular diagnostic tools were not employed. The objective of this study was to review the incidence of PJP during and post‐FCR in the era of highly sensitive molecular diagnostics and (18)F‐fluorodeoxyglucose (FDG) positron emission tomography (PET)–computerised tomography (CT). METHODS: All patients treated with standard FCR at the Peter MacCallum Cancer Centre (March 2009 to June 2012) were identified from a medications management database. Laboratory‐confirmed PJP cases during this time were identified from an electronic database. RESULTS: Overall, 66 patients were treated with a median of 5.5 FCR cycles. Eight PJP cases were identified, 6 of whom had received chemotherapy prior to FCR. In 5 cases, (18)F‐FDG PET demonstrated bilateral ground‐glass infiltrates. Median CD4(+) lymphocyte counts at time of PJP diagnosis and 9–12 months following FCR were 123 and 400 cells/μL, respectively. In patients receiving no prophylaxis, 9.1% developed PJP during FCR. The rate following FCR was 18.4%, with median onset at 6 months (2.4–24 months). CONCLUSION: Given the high rate of late‐onset PJP, consideration should be given for extended PJP prophylaxis for up to 12 months post‐FCR, particularly in pretreated patients. Further evaluation of the role of CD4(+) monitoring is warranted to quantify risk of disease development and to guide duration of prophylaxis.
has issue date	2013-06-15(xsd:dateTime)
bibo:doi	10.1111/ejh.12135
bibo:pmid	23668894
has license	no-cc
sha1sum (hex)	173b63533b5fcd6e6fd4b1058befa12b0319431e
schema:url	https://doi.org/10.1111/ejh.12135
resource representing a document's title	Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis
has PubMed Central identifier	PMC7163499
has PubMed identifier	23668894
schema:publication	Eur J Haematol
resource representing a document's body	covid:173b63533b5fcd6e6fd4b1058befa12b0319431e#body_text
is schema:about of	named entity 'FCR' named entity 'FDG' named entity 'prophylaxis' named entity 'INCIDENCE' named entity 'GROUND' named entity 'RISK OF' named entity 'MANAGEMENT' named entity 'DISEASE' named entity 'GIVEN' named entity 'MONTHS' named entity 'FDG PET' named entity '400' named entity 'GLASS' named entity 'EVALUATION' named entity 'DIAGNOSIS' named entity 'risk' named entity 'treated' named entity 'prophylaxis' named entity 'standard' named entity 'receiving' named entity 'CD4' named entity 'FCR' named entity 'high' named entity 'All' named entity 'studies' named entity 'demonstrated' named entity 'chemotherapy' named entity 'June' named entity 'March' named entity 'cyclophosphamide' named entity 'PJP' named entity 'CD4 +' named entity 'lymphoid malignancies' named entity '5.5' named entity 'PET' named entity 'PJP' named entity 'PJP' named entity 'Fludarabine' named entity 'PJP' named entity 'fludarabine' named entity 'cyclophosphamide' named entity 'prophylaxis' named entity 'prophylaxis' named entity 'infection' named entity 'chronic lymphocytic leukaemia' named entity 'vincristine' named entity 'CD4 +' named entity 'Roche' named entity 'pneumonitis' named entity 'HSV-2' named entity 'chlorambucil' named entity 'microscopy' named entity 'CD4 +' named entity 'prophylaxis' named entity 'PET' named entity 'randomised trials' named entity 'neutropenic' named entity 'Quantitative PCR' named entity 'randomised controlled trials' named entity 'infection' named entity 'MAS' named entity 'lymphocyte count' named entity 'chemotherapy' named entity 'PCR' named entity 'PJP' named entity 'PJP' named entity 'causal relationship' named entity 'bronchoalveolar lavage' named entity 'Mycobacterium' named entity 'haematological malignancies' named entity 'pathogens' named entity 'unexplained fever'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software